Navigation Links
Peregrine Pharmaceuticals Reports Financial Results for the First Quarter of Fiscal Year 2009
Date:9/9/2008

brain cancer.

Other Developments

-- Avid Bioservices became the first U.S. pre-approved contract manufacturer for licensees of the DSM Biologics and Crucell PER.C6(R) cell line, a proprietary high yield cell line with important advantages over other approaches.

-- Received a Staff Determination letter from the Nasdaq Stock Market indicating that the company was not in compliance with the $1.00 minimum bid price requirement for continued listing. On September 4, 2008, Peregrine attended an oral hearing with an independent Nasdaq Panel and Peregrine requested an additional 180 days to regain compliance, or until January 20, 2009. The final written decision from Nasdaq is expected within 30 days of the hearing date.

Conference Call

The company will host a conference call today, September 9, 2008 at 11:30 a.m. EDT/8:30 a.m. PDT to discuss its First Quarter FY 2009 financial results.

To listen to a live broadcast of the call over the Internet or to review the archived call, please visit: http://www.peregrineinc.com. The webcast will be archived on Peregrine's website for approximately 30 days.

To listen to the conference call via telephone, please call the following number approximately 10 minutes prior to the scheduled start time and request to join the Peregrine Pharmaceuticals call: (800) 860-2442. A telephonic replay of the conference call will be available starting approximately one hour after the conclusion of the call through September 16, 2008 by calling (877) 344-7529, passcode 382933#.

About Peregrine Pharmaceuticals

Peregrine Pharmaceuticals, Inc. is a biopharmaceutical company with a portfolio of innovative product candidates in clinical trials for the treatment of cancer and hepatitis C virus (HCV) infection. The company is pursuing three separate clinical programs in cancer and HCV infection with its lead product candidates bavituximab and
'/>"/>

SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. Peregrine Pharmaceuticals to Report First Quarter FY 2009 Financial Results
2. Peregrine Pharmaceuticals Receives Letter from NASDAQ Citing Failure to Regain Compliance with Minimum Bid Price Rule
3. Peregrine Pharmaceuticals Reports Financial Results for Fiscal Year 2008
4. Peregrine Pharmaceuticals Awarded DTRA Contract Worth up to $44.4 Million to Develop Bavituximab for Viral Hemorrhagic Fevers
5. Peregrine Pharmaceuticals Presents Promising Phase I Data at ASCO and Provides Clinical Update on Its Phase II Bavituximab Breast Cancer Study
6. Peregrine Pharmaceuticals Reports Studies Published in Science Highlight Key Role of Phosphatidylserine (PS) in Viral Infections
7. Peregrine Pharmaceuticals Announces Four Upcoming Presentations at the American Association for Cancer Research 2008 Annual Meeting
8. Peregrine Pharmaceuticals Reports Financial Results for the Third Quarter of Fiscal Year 2008
9. Peregrine Pharmaceuticals to Announce Third Quarter FY 2008 Financial Results
10. Publication in Clinical Cancer Research Confirms Ability of Peregrines Bavituximab to Target Tumor Blood Vessels with Excellent Specificity
11. Peregrine Pharmaceuticals Doses First Patient in Phase II Clinical Trial of Bavituximab in Patients With Advanced Breast Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/30/2014)... Grace Century portfolio project, Provia Laboratories , ... the Board, to the National Stem Cell Ethics Committee ... by the Ministry of Health on behalf of the Government ... More than a year after Bahamian Parliament passed the ... Christie said the government has completed the accompanying regulations and ...
(Date:10/30/2014)... that devastated a wide swath of Colorado last year ... and other infrastructure had been upgraded or modernized, according ... Denver. , "People need to understand the importance and ... of structural engineering at the CU Denver College of ... "There is an assumption that a bridge will stand ...
(Date:10/27/2014)... , Oct. 27, 2014 Kalorama Information ... recent Ebola concern in the United States ... virus.  The healthcare market researcher said the FDA,s Emergency Use ... vitro diagnostic tests for the detection of the Ebola ... proved useful.  Kalorama routinely assess the IVD industry and ...
(Date:10/27/2014)... 27, 2014 Pressure BioSciences, Inc. (OTCQB: ... in the development and sale of high pressure-based ... market, today announced that Professor Ruedi Aebersold ... highly reproducible, and robust method to allow – ... analysis on small needle biopsy samples by mass ...
Breaking Biology Technology:Grace Century’s Stem Cell Biobank Project Announces Chairman’s Appointment to National Stem Cell Ethics Committee of The Bahamas 2Grace Century’s Stem Cell Biobank Project Announces Chairman’s Appointment to National Stem Cell Ethics Committee of The Bahamas 3CU Denver study says upgrading infrastructure could reduce flood damage 2Kalorama: PCR The Go-to Test in Ebola Fight 2Kalorama: PCR The Go-to Test in Ebola Fight 3Breakthrough Method to Permit Quantification of Thousands of Proteins in Needle Biopsy Samples in 12 hours Presented at Major International Scientific Meeting; Method Enabled by Pressure BioSciences' PCT Sample Preparation Platform 2Breakthrough Method to Permit Quantification of Thousands of Proteins in Needle Biopsy Samples in 12 hours Presented at Major International Scientific Meeting; Method Enabled by Pressure BioSciences' PCT Sample Preparation Platform 3Breakthrough Method to Permit Quantification of Thousands of Proteins in Needle Biopsy Samples in 12 hours Presented at Major International Scientific Meeting; Method Enabled by Pressure BioSciences' PCT Sample Preparation Platform 4Breakthrough Method to Permit Quantification of Thousands of Proteins in Needle Biopsy Samples in 12 hours Presented at Major International Scientific Meeting; Method Enabled by Pressure BioSciences' PCT Sample Preparation Platform 5
... CR Approved and Launched - Screening Closed ... ALTO, Calif., May 13 Jazz,Pharmaceuticals, Inc. (Nasdaq: ... March 31, 2008., Total revenues for the quarter ... million for the quarter ended March 31, 2007. XYREM(R),(sodium ...
... When Sergeant Heather Maddy of the,325th Combat Support Hospital ... inquiring about a desperately needed piece,of critical care equipment ... expected one to be delivered within days -- free ... that we received the Doppler [System] a,few days ago!" ...
... China Sky One,Medical, Inc. (OTC Bulletin Board: CSKI) ... developer, manufacturer, marketer and,international distributor of pharmaceutical, medicinal ... the first quarter,ended March 31, 2008., ... Quarter 2007 (All first quarter numbers are ...
Cached Biology Technology:Jazz Pharmaceuticals, Inc. Announces First Quarter 2008 Financial Results 2Jazz Pharmaceuticals, Inc. Announces First Quarter 2008 Financial Results 3Jazz Pharmaceuticals, Inc. Announces First Quarter 2008 Financial Results 4Jazz Pharmaceuticals, Inc. Announces First Quarter 2008 Financial Results 5Jazz Pharmaceuticals, Inc. Announces First Quarter 2008 Financial Results 6Jazz Pharmaceuticals, Inc. Announces First Quarter 2008 Financial Results 7Jazz Pharmaceuticals, Inc. Announces First Quarter 2008 Financial Results 8Serving Those Who Serve Our Country: Medical Device Company Answers the Call of a U.S. Combat Hospital in Iraq 2China Sky One Medical, Inc. Announces Record First Quarter 2008 Results 2China Sky One Medical, Inc. Announces Record First Quarter 2008 Results 3China Sky One Medical, Inc. Announces Record First Quarter 2008 Results 4China Sky One Medical, Inc. Announces Record First Quarter 2008 Results 5China Sky One Medical, Inc. Announces Record First Quarter 2008 Results 6China Sky One Medical, Inc. Announces Record First Quarter 2008 Results 7China Sky One Medical, Inc. Announces Record First Quarter 2008 Results 8China Sky One Medical, Inc. Announces Record First Quarter 2008 Results 9China Sky One Medical, Inc. Announces Record First Quarter 2008 Results 10
(Date:10/29/2014)... stem cell, those referred to as ,facultative, form part—together ... nothing that differentiates these cells from the others. However, ... the capacity to become stem cells again. This phenomenon ... that hosts cells that stimulate tissue growth, thus allowing ... a transplant. Knowledge of the underlying mechanism that ...
(Date:10/29/2014)... – Ghrelin is a hormone released by the stomach ... commonly viewed as a psychoactive substance that primarily affects ... food. , This knowledge, combined with findings from ... has the potential to stimulate alcohol craving. , Dr. ... and found that, as they had anticipated, alcohol craving ...
(Date:10/28/2014)... German . ... sufficient food when times are lean? By studying wild ... researchers of the Max Planck Institute for Evolutionary Anthropology ... great apes can acquire extra energy needed to maintain ... sleeping nests more en route to breakfast sites containing ...
Breaking Biology News(10 mins):A mechanism that allows a differentiated cell to reactivate as a stem cell revealed 2Ghrelin stimulates an appetite for drinking alcohol 2The early chimp gets the fig 2The early chimp gets the fig 3
... The Wildlife Conservation Society tracked a southern elephant seal ... York to Sydney and back again. , WCS tracked the ... animal nicknamed Jackson was tagged on the beach ... WCS conservationists fitted Jackson with a small satellite transmitter that ...
... Therapeutics, Inc. announced today promising clinical results ... umbilical cord blood) as part of double-umbilical cord ... malignancies who have undergone reduced-intensity conditioning therapy.  The ... American Society of Hematology (ASH) meeting, being held ...
... of Toronto have found an explanation for how the ... system to prevent infection, offering a potential clue to ... multiple sclerosis. "The findings shed light on the ... gut," said Prof. Jennifer Gommerman, an Associate Professor in ...
Cached Biology News:Elephant seal travels 18,000 miles 2Fate Therapeutics Announces Promising Data From Phase 1b Study of ProHema at the 2011 American Society of Hematology Annual Conference 2Fate Therapeutics Announces Promising Data From Phase 1b Study of ProHema at the 2011 American Society of Hematology Annual Conference 3Fate Therapeutics Announces Promising Data From Phase 1b Study of ProHema at the 2011 American Society of Hematology Annual Conference 4Intestine crucial to function of immune cells, research shows 2Intestine crucial to function of immune cells, research shows 3